This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the potential of AXS-07, an oral multi-mechanistic investigational medicine for the acute treatment of migraine

Ticker(s): AXSM

Who's the expert?

Institution: The Neurology Center

  • Neurologist who treats 250 patients with migraine
  • Reviewing the AXS-07 data before call

Interview Goal
Discussing the potential of AXS-07, an oral multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC meloxicam and rizatriptan (currently in development by Axsome).

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.